Jan 5 (Reuters) - Valeant Pharmaceuticals International Inc (N:VRX)
VRX.TO VRX.N is planning to appoint a new CEO as Chief
Executive Michael Pearson (L:PSON) remains hospitalized, CNBC tweeted,
citing Dow Jones.
The new chief executive would replace the committee
currently running the company, CNBC tweeted, citing Dow Jones.
The Canadian drugmaker last week said a group of company
executives will immediately take over for its chief executive
until he returns from medical leave.
Valeant could not be immediately reached for comment outside
normal business hours.